Role of serum prothrombin induced by vitamin K absence or antagonist-II in the early detection of hepatocellular carcinoma in patients with chronic hepatitis B virus infection

References

• Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001; 94: 153–6
   PubMed Web of Science ®Google Scholar
• Collier J, Sherman M. Screening for hepatocellular carcinoma. Hepatology 1998; 27: 273–8
   PubMed Web of Science ®Google Scholar
• Di Bisceglie AM. Hepatitis C and hepatocellular carcinoma. Hepatology 1997; 26: 34S–8S
   PubMed Web of Science ®Google Scholar
• Zaman SN, Johnson PJ, Williams R. Silent cirrhosis in patients with hepatocellular carcinoma. Implications for screening in high-incidence and low-incidence areas. Cancer 1990; 65: 1607–10
   PubMedGoogle Scholar
• McMahon BJ. Epidemiology and natural history of hepatitis B. Semin Liver Dis 2005; 25S: 3–8
   Google Scholar
• Sherman M. Surveillance for hepatocellular carcinoma and early diagnosis. Clin Liver Dis 2007; 11: 817–37
   PubMedGoogle Scholar
• Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003; 362: 1907–17
   PubMed Web of Science ®Google Scholar
• Wong GL, Wong VW, Tan GM, Ip KI, Lai WK, Li YW, et al. Surveillance programme for hepatocellular carcinoma improves the survival of patients with chronic viral hepatitis. Liver Int 2008; 28: 79–87
   PubMedGoogle Scholar
• Yuen MF, Lai CL. Serological markers of liver cancer. Best Pract Res Clin Gastroenterol 2005; 19: 91–9
   PubMed Web of Science ®Google Scholar
• Trevisani F, D'Intino PE, Morselli-Labate AM, Mazzella G, Accogli E, Caraceni P, et al. Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. J Hepatol 2001; 34: 570–5
   PubMed Web of Science ®Google Scholar
• Gupta S, Bent S, Kohlwes J. Test characteristics of alpha-fetoprotein for detecting hepatocellular carcinoma in patients with hepatitis C. A systematic review and critical analysis. Ann Intern Med 2003; 139: 46–50
   PubMed Web of Science ®Google Scholar
• Fujiyama S, Tanaka M, Maeda S, Ashihara H, Hirata R, Tomita K. Tumor markers in early diagnosis, follow-up and management of patients with hepatocellular carcinoma. Oncology 2002; 62S: 57–63
   Google Scholar
• Sherman M. Alphafetoprotein: an obituary. J Hepatol 2001; 34: 603–5
   PubMed Web of Science ®Google Scholar
• Liebman HA, Furie BC, Tong MJ, Blanchard RA, Lo KJ, Lee SD, et al. Des-gamma-carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma. N Engl J Med 1984; 310: 1427–31
   PubMed Web of Science ®Google Scholar
• Grazi GL, Mazziotti A, Legnani C, Jovine E, Miniero R, Ballucci A, et al. The role of tumor markers in the diagnosis of hepatocellular carcinoma, with special reference to the des-gamma-carboxy prothrombin. Liver Transpl Surg 1995; 1: 249–55
   PubMedGoogle Scholar
• Ishii M, Gama H, Chida N, Ueno Y, Shinzawa H, Takagi T, et al. Simultaneous measurements of serum alpha-fetoprotein and protein induced by vitamin K absence for detecting hepatocellular carcinoma. South Tohoku District Study Group. Am J Gastroenterol 2000; 95: 1036–40
   PubMedGoogle Scholar
• Weitz IC, Liebman HA. Des-gamma-carboxy (abnormal) prothrombin and hepatocellular carcinoma: a critical review. Hepatology 1993; 18: 990–7
   PubMedGoogle Scholar
• Marrero JA, Su GL, Wei W, Emick D, Conjeevaram HS, Fontana RJ, et al. Des-gamma-carboxy prothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in American patients. Hepatology 2003; 37: 1114–21
   PubMed Web of Science ®Google Scholar
• Koike Y, Shiratori Y, Sato S, Obi S, Teratani T, Imamura M, et al. Des-gamma-carboxy prothrombin as a useful predisposing factor for the development of portal venous invasion in patients with hepatocellular carcinoma: a prospective analysis of 227 patients. Cancer 2001; 91: 561–9
   PubMed Web of Science ®Google Scholar
• Liver Cancer Study Group of Japan. The general rules for the clinical and pathological study of primary liver cancer, 4th ed. Tokyo, Japan: Kanehara & Co. Ltd.; 2000.
   Google Scholar
• Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, et al. EASL panel of experts on HCC: clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001; 35: 421–30
   PubMed Web of Science ®Google Scholar
• Yuen MF, Lai CL. Screening for hepatocellular carcinoma: survival benefit and cost-effectiveness. Ann Oncol 2003; 14: 1463–7
   PubMedGoogle Scholar
• Tremolda F, Benevegnù L, Drago C, Casarin C, Cechetto A, Realdi G, et al. Early detection of hepatocellular carcinoma in patients with cirrhosis by alphafetoprotein, ultrasound and fine-needle biopsy. Hepatogastroenterology 1989; 36: 519–21
   PubMedGoogle Scholar
• Gambarin-Gelwan M, Wolf DC, Shapiro R, Schwartz ME, Min AD. Sensitivity of commonly available screening tests in detecting hepatocellular carcinoma in cirrhotic patients undergoing liver transplantation. Am J Gastroenterol 2000; 95: 1535–8
   PubMed Web of Science ®Google Scholar
• Nakamura S, Nouso K, Sakaguchi K, Ito YM, Ohashi Y, Kobayashi Y, et al. Sensitivity and specificity of des-gamma-carboxy prothrombin for diagnosis of patients with hepatocellular carcinomas varies according to tumor size. Am J Gastroenterol 2006; 101: 2038–43
   PubMed Web of Science ®Google Scholar
• Teefey SA, Hildeboldt CC, Dehdashti F, Siegel BA, Peters MG, Heiken JP, et al. Detection of primary hepatic malignancy in liver transplant candidates: prospective comparison of CT, MR imaging, US, and PET. Radiology 2003; 226: 533–42
   PubMed Web of Science ®Google Scholar
• Yao FY, Ferrell L, Bass NM, Watson JJ, Bacchetti P, Venook A, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 2001; 33: 1394–403
   PubMed Web of Science ®Google Scholar
• Nagaoka S, Yatsuhashi H, Hamada H, Yano K, Matsumoto T, Daikoku M, et al. The des-gamma-carboxy prothrombin index is a new prognostic indicator for hepatocellular carcinoma. Cancer 2003; 98: 2671–7
   PubMedGoogle Scholar